The DOI matches its Crossref record; 411 of the 411 references it cites were found in a registry or an index.
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Open accessAbstract
T cells play a critical role in cancer control, but a range of potent immunosuppressive mechanisms can be upregulated in the tumor microenvironment (TME) to abrogate their activity. While various immunotherapies (IMTs) aiming at re-invigorating the T-cell-mediated anti-tumor response, such as immune checkpoint blockade (ICB), and the adoptive cell transfer (ACT) of natural or gene-engineered ex vivo expanded tumor-specific T cells, have led to unprecedented clinical responses, only a small proportion of cancer patients benefit from these treatments. Important research efforts are thus underway to identify biomarkers of response, as well as to develop personalized combinatorial approaches that can target other inhibitory mechanisms at play in the TME. In recent years, adenosinergic signaling has emerged as a powerful immuno-metabolic checkpoint in tumors. Like several other barriers in the TME, such as the PD-1/PDL-1 axis, CTLA-4, and indoleamine 2,3-dioxygenase (IDO-1), adenosine plays important physiologic roles, but has been co-opted by tumors to promote their growth and impair immunity. Several agents counteracting the adenosine axis have been developed, and pre-clinical studies have demonstrated important anti-tumor activity, alone and in combination with other IMTs including ICB and ACT. Here we review the regulation of adenosine levels and mechanisms by which it promotes tumor growth and broadly suppresses protective immunity, with extra focus on the attenuation of T cell function. Finally, we present an overview of promising pre-clinical and clinical approaches being explored for blocking the adenosine axis for enhanced control of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470
CREB: A Stimulus-Induced Transcription Factor Activated by A Diverse Array of Extracellular Signals
Shaywitz, A. J., & Greenberg, M. E. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.821 · Cited by 2,134
Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP
de Rooij, J., Zwartkruis, F. J. T., Verheijen, M. H. G., Cool, R. H., Nijman, S. M. B., Wittinghofer, A., & Bos, J. L. (1998) · Nature · doi:10.1038/24884 · Cited by 1,969
Mechanisms and regulation of endothelial VEGF receptor signalling
Simons, M., Gordon, E., & Claesson-Welsh, L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.87 · Cited by 1,498
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360 · cited 3×
“Blockade of the PD-1-PDL-1/2 signaling axis results in durable complete responses in the clinic for a fraction of treated patients (1), and many pre-clinical and clinical studies have explored concomitant inhibition of adenosine production, or antagonism of A2AR and A2BR, to improve response rates.”
BackgroundInfluentialFredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
Yegutkin, G. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.024 · Cited by 1,154
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
Swaminathan, B., Thorleifsson, G., Jöud, M., Ali, M., Johnsson, E., Ajore, R., Sulem, P., Halvarsson, B.-M., Eyjolfsson, G., Haraldsdottir, V., et al. (2015) · Nature Communications · doi:10.1038/ncomms8213 · Cited by 1,132
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
BioNumbers—the database of key numbers in molecular and cell biology
Milo, R., Jorgensen, P., Moran, U., Weber, G., & Springer, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp889 · Cited by 1,055
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals
Altarejos, J. Y., & Montminy, M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3072 · Cited by 1,040
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Cellular function and molecular structure of ecto-nucleotidases
Zimmermann, H., Zebisch, M., & Sträter, N. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9309-4 · Cited by 977
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
The role of the transcription factor CREB in immune function
Wen, A. Y., Sakamoto, K. M., & Miller, L. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001829 · Cited by 790
Purinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Transcriptional regulation by hypoxia inducible factors
Dengler, V. L., Galbraith, M. D., & Espinosa, J. M. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.838205 · Cited by 782
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Di Virgilio, F., Sarti, A. C., Falzoni, S., De Marchi, E., & Adinolfi, E. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0037-0 · Cited by 723
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679
Cyclic adenosine monophosphate is a key component of regulatory T cell–mediated suppression
Bopp, T., Becker, C., Klein, M., Klein-Heßling, S., Palmetshofer, A., Serfling, E., Heib, V., Becker, M., Kubach, J., Schmitt, S., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062129 · Cited by 658
Nanomaterials in Targeting Cancer Stem Cells for Cancer Therapy
Qin, W., Huang, G., Chen, Z., & Zhang, Y. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00001 · Cited by 656
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Domanska, U. M., Kruizinga, R. C., Nagengast, W. B., Timmer-Bosscha, H., Huls, G., de Vries, E. G. E., & Walenkamp, A. M. E. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.005 · Cited by 635
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Schreiber, T. H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa1260 · Cited by 600
The functional network of ion channels in T lymphocytes
Cahalan, M. D., & Chandy, K. G. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00816.x · Cited by 599
CREB/ATF-dependent T cell receptor–induced FoxP3 gene expression: a role for DNA methylation
Kim, H.-P., & Leonard, W. J. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070109 · Cited by 597
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citationAnti-CD73 antibody therapy inhibits breast tumor growth and metastasis
Stagg, J., Divisekera, U., McLaughlin, N., Sharkey, J., Pommey, S., Denoyer, D., Dwyer, K. M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908801107 · Cited by 572
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571
Erdogan, B., & Webb, D. J. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160387 · Cited by 558
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Targeting adenosine for cancer immunotherapy
Leone, R. D., & Emens, L. A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0360-8 · Cited by 543
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540 · cited 1×
“In addition, CD39/CD73-bearing exosomes (69, 70), released by tumor cells (71), Tregs (72), and MDSCs (57, 73) further contribute to adenosine generation.”
BackgroundHaskó, G., Szabó, C., Németh, Z. H., Kvetan, V, Pastores, S. M., & Vizi, E. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.10.4634 · Cited by 536
Huang, S., Apasov, S., Koshiba, M., & Sitkovsky, M. (1997) · Blood · doi:10.1182/blood.v90.4.1600 · Cited by 531
Zarek, P. E., Huang, C.-T., Lutz, E. R., Kowalski, J., Horton, M. R., Linden, J., Drake, C. G., & Powell, J. D. (2008) · Blood · doi:10.1182/blood-2007-03-081646 · Cited by 515
Haskó, G., Kuhel, D. G., Chen, J.-F., Schwarzschild, M. A., Deitch, E. A., Mabley, J. G., Marton, A., & Szabó, C. (2000) · The FASEB Journal · doi:10.1096/fj.99-0508com · Cited by 512
G-protein signaling: back to the future
McCudden, C. R., Hains, M. D., Kimple, R. J., Siderovski, D. P., & Willard, F. S. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4462-3 · Cited by 505
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Loi, S., Pommey, S., Haibe-Kains, B., Beavis, P. A., Darcy, P. K., Smyth, M. J., & Stagg, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222251110 · Cited by 492
Skalhegg, B. (2000) · Frontiers in Bioscience · doi:10.2741/skalhegg · Cited by 482
Design of Antibacterial Agents: Alkyl Dihydroxybenzoates against Xanthomonas citri subsp. citri
Nazaré, A. C., Polaquini, C. R., Cavalca, L. B., Anselmo, D. B., Saiki, M. D. F. C., Monteiro, D. A., Zielinska, A., Rahal, P., Gomes, E., Scheffers, D.-J., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103050 · Cited by 475
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462 · cited 13×
“Moreover, A2AR activation promotes IL-10 production by MDSCs (314) and treatment with an adenosine analog results in increased expression of CD73 (313).”
BackgroundInfluentialTargeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Allard, B., Pommey, S., Smyth, M. J., & Stagg, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0545 · Cited by 458
Egr-2 and Egr-3 are negative regulators of T cell activation
Safford, M., Collins, S., Lutz, M. A., Allen, A., Huang, C.-T., Kowalski, J., Blackford, A., Horton, M. R., Drake, C., Schwartz, R. H., et al. (2005) · Nature Immunology · doi:10.1038/ni1193 · Cited by 445
(1997) · PubMed · Cited by 433
Jin, D., Fan, J., Wang, L., Thompson, L. F., Liu, A., Daniel, B. J., Shin, T., Curiel, T. J., & Zhang, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3109 · Cited by 432
HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer
Barnes, T. A., & Amir, E. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.220 · Cited by 432
Adenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430 · cited 4×
“Moreover, such DCs are less motile due to chemokine receptor downregulation (274), and have a tolerogenic effect on the TME due to overexpression of TGFβ (267), IL-10, IDO-1 (267), arginase-2 (267, 275), as well as A2AR-mediated upregulation of PD-L2 (276).”
BackgroundInfluentialHino, S.-I., Tanji, C., Nakayama, K. I., & Kikuchi, A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.20.9063-9072.2005 · Cited by 427
Purinergic Control of T Cell Activation by ATP Released Through Pannexin-1 Hemichannels
Schenk, U., Westendorf, A. M., Radaelli, E., Casati, A., Ferro, M., Fumagalli, M., Verderio, C., Buer, J., Scanziani, E., & Grassi, F. (2008) · Science Signaling · doi:10.1126/scisignal.1160583 · Cited by 411
Maintenance of Human T Cell Anergy: Blocking of IL-2 Gene Transcription by Activated Rap1
Boussiotis, V. A., Freeman, G. J., Berezovskaya, A., Barber, D. L., & Nadler, L. M. (1997) · Science · doi:10.1126/science.278.5335.124 · Cited by 409
CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells
Canale, F. P., Ramello, M. C., Núñez, N., Furlan, C. L. A., Bossio, S. N., Serrán, M. G., Boari, J. T., del Castillo, A., Ledesma, M., Sedlik, C., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-16-2684 · Cited by 408
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
Dynamics of cAMP-Dependent Protein Kinase
Johnson, D. A., Akamine, P., Radzio-Andzelm, E., Madhusudan, & Taylor, S. S. (2001) · Chemical Reviews · doi:10.1021/cr000226k · Cited by 393
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
Young, A., Ngiow, S. F., Barkauskas, D. S., Sult, E., Hay, C., Blake, S. J., Huang, Q., Liu, J., Takeda, K., Teng, M. W. L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.025 · Cited by 388
A2A Adenosine Receptor Induction Inhibits IFN-γ Production in Murine CD4+ T Cells
Lappas, C. M., Rieger, J. M., & Linden, J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.1073 · Cited by 385
Keravis, T., & Lugnier, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01729.x · Cited by 385
Adenosine promotes alternative macrophage activation via A2A and A2B receptors
Csóka, B., Selmeczy, Z., Koscsó, B., Németh, Z. H., Pacher, P., Murray, P. J., Kepka‐Lenhart, D., Jr., S. M. M., Gause, W. C., Leibovich, S. J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190934 · Cited by 376
Ferrante, C. J., Pinhal-Enfield, G., Elson, G., Cronstein, B. N., Hasko, G., Outram, S., & Leibovich, S. J. (2013) · Inflammation · doi:10.1007/s10753-013-9621-3 · Cited by 375
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Self-citationCronstein, B. N., Levin, R. I., Philips, M., Hirschhorn, R., Abramson, S. B., & Weissmann, G. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.148.7.2201 · Cited by 365
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors
Sajjadi, F. G., Takabayashi, K., Foster, A. C., Domingo, R. C., & Firestein, G. S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.9.3435 · Cited by 352
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
Eltzschig, H. K., Abdulla, P., Hoffman, E., Hamilton, K. E., Daniels, D., Schönfeld, C., Löffler, M., Reyes, G., Duszenko, M., Karhausen, J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050177 · Cited by 351
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
Epac and PKA: a tale of two intracellular cAMP receptors
Cheng, X., Ji, Z., Tsalkova, T., & Mei, F. (2008) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2008.00438.x · Cited by 340
Lawson, J. S., Salmons, B., & Glenn, W. K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00001 · Cited by 340
Chalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338
Beavis, P. A., Milenkovski, N., Henderson, M. A., John, L. B., Allard, B., Loi, S., Kershaw, M. H., Stagg, J., & Darcy, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0211 · Cited by 334
Ludwig, S., Floros, T., Theodoraki, M.-N., Hong, C.-S., Jackson, E. K., Lang, S., & Whiteside, T. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2819 · Cited by 334
Vang, T., Torgersen, K. M., Sundvold, V., Saxena, M., Levy, F. O., Skålhegg, B. S., Hansson, V., Mustelin, T., & Taskén, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.4.497 · Cited by 330
Mascanfroni, I. D., Yeste, A., Vieira, S. M., Burns, E. J., Patel, B., Sloma, I., Wu, Y., Mayo, L., Ben-Hamo, R., Efroni, S., et al. (2013) · Nature Immunology · doi:10.1038/ni.2695 · Cited by 329
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Beavis, P. A., Henderson, M. A., Giuffrida, L., Mills, J. K., Sek, K., Cross, R. S., Davenport, A. J., John, L. B., Mardiana, S., Slaney, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89455 · Cited by 325
Serine phosphorylation negatively regulates RhoA in vivo
Ellerbroek, S. M., Wennerberg, K., & Burridge, K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213066200 · Cited by 315
Kreutzmann, J. C., Havekes, R., Abel, T., & Meerlo, P. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.053 · Cited by 309
Cekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
A2B adenosine receptor dampens hypoxia-induced vascular leak
Eckle, T., Faigle, M., Grenz, A., Laucher, S., Thompson, L. F., & Eltzschig, H. K. (2008) · Blood · doi:10.1182/blood-2007-10-117044 · Cited by 302
Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320011 · Cited by 299
Layland, J., Carrick, D., Lee, M., Oldroyd, K., & Berry, C. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.02.009 · Cited by 297
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
Németh, Z. H., Lutz, C. S., Csóka, B., Deitch, E. A., Leibovich, S. J., Gause, W. C., Tone, M., Pacher, P., Vizi, E. S., & Haskó, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.12.8260 · Cited by 291
Targeting CD73 in the tumor microenvironment with MEDI9447
Hay, C. M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S. R., McGlinchey, K. A., Hammond, S. A., Rothstein, R., Rios-Doria, J., Poon, E., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1208875 · Cited by 287
Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Müller, C. E., Murakami, T., & Robson, S. C. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.007 · Cited by 279
Horenstein, A. L., Chillemi, A., Zaccarello, G., Bruzzone, S., Quarona, V., Zito, A., Serra, S., & Malavasi, F. (2013) · OncoImmunology · doi:10.4161/onci.26246 · Cited by 279
Pinhal-Enfield, G., Ramanathan, M., Hasko, G., Vogel, S. N., Salzman, A. L., Boons, G.-J., & Leibovich, S. J. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63698-x · Cited by 278 · cited 1×
“In addition, by triggering A2AR (282, 286, 287), A2BR (288, 289) or unidentified ARs, adenosine promotes an M2 polarization of macrophages by inducing upregulation of arginase-1 (288, 290), IL-10 (279, 286, 289) and VEGF production (282, 287).”
BackgroundChemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Schuler, P. J., Saze, Z., Hong, C.-S., Muller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12354 · Cited by 277
Adenosine A 2A Receptor as a Drug Discovery Target
de Lera Ruiz, M., Lim, Y.-H., & Zheng, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011669 · Cited by 276
Smyth, L. A., Ratnasothy, K., Tsang, J. Y. S., Boardman, D., Warley, A., Lechler, R., & Lombardi, G. (2013) · European Journal of Immunology · doi:10.1002/eji.201242909 · Cited by 275
Dong, J.-M., Leung, T., Manser, E., & Lim, L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.35.22554 · Cited by 271
Feoktistov, I., Goldstein, A. E., Ryzhov, S., Zeng, D., Belardinelli, L., Voyno-Yasenetskaya, T., & Biaggioni, I. (2002) · Circulation Research · doi:10.1161/01.res.0000012203.21416.14 · Cited by 270
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 269
Li, L., Wang, L., Li, J., Fan, Z., Yang, L., Zhang, Z., Zhang, C., Yue, D., Qin, G., Zhang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2460 · Cited by 266
Hypoxia-Induced Inhibition of Adenosine Kinase Potentiates Cardiac Adenosine Release
Decking, U. K. M., Schlieper, G., Kroll, K., & Schrader, J. (1997) · Circulation Research · doi:10.1161/01.res.81.2.154 · Cited by 265
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56δ subunit
Ahn, J.-H., McAvoy, T., Rakhilin, S. V., Nishi, A., Greengard, P., & Nairn, A. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611532104 · Cited by 264
Dipyridamole inhibition of adenosine metabolism in human blood
Klabunde, R. E. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90026-2 · Cited by 263
CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
Wang, L., Fan, J., Thompson, L. F., Zhang, Y., Shin, T., Curiel, T. J., & Zhang, B. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45559 · Cited by 262
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261
MacKenzie, S. J., Baillie, G. S., McPhee, I., MacKenzie, C., Seamons, R., McSorley, T., Millen, J., Beard, M. B., van Heeke, G., & Houslay, M. D. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704743 · Cited by 260
Regulation of Neutrophil Function by Adenosine
Barletta, K. E., Ley, K., & Mehrad, B. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226845 · Cited by 260
CD3- and CD28-Dependent Induction of PDE7 Required for T Cell Activation
Li, L., Yee, C., & Beavo, J. A. (1999) · Science · doi:10.1126/science.283.5403.848 · Cited by 259
Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases
Cronstein, B. N., & Sitkovsky, M. (2017) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.178 · Cited by 258
Adenylyl Cyclase–A-kinase Anchoring Protein Complexes: The Next Dimension in cAMP Signaling
Dessauer, C. W. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.059345 · Cited by 254
Dumaz, N., & Marais, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300182200 · Cited by 252
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
Mittal, D., Young, A., Stannard, K., Yong, M., Teng, M. W. L., Allard, B., Stagg, J., & Smyth, M. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0957 · Cited by 245
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
Eltzschig, H. K., Köhler, D., Eckle, T., Kong, T., Robson, S. C., & Colgan, S. P. (2009) · Blood · doi:10.1182/blood-2008-06-165746 · Cited by 244
Skalhegg, B. S. (1997) · Frontiers in Bioscience · doi:10.2741/a195 · Cited by 242
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0018 · Cited by 240
Tian, Y., Xie, Q., He, J., Luo, X., Zhou, T., Liu, Y., Huang, Z., Tian, Y., Sun, D., & Yao, K. (2015) · BMC Cancer · doi:10.1186/1471-2407-15-1 · Cited by 239
Johnston, A., Gudjonsson, J. E., Sigmundsdottir, H., Runar Ludviksson, B., & Valdimarsson, H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.09.001 · Cited by 231
Panther, E., Corinti, S., Idzko, M., Herouy, Y., Napp, M., la Sala, A., Girolomoni, G., & Norgauer, J. (2003) · Blood · doi:10.1182/blood-2002-07-2113 · Cited by 229
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci46266 · Cited by 229
The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging
Chini, E. N., Chini, C. C. S., Espindola Netto, J. M., de Oliveira, G. C., & van Schooten, W. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.001 · Cited by 227
Regulation of Macrophage Function by Adenosine
Haskó, G., & Pacher, P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226852 · Cited by 223
Ohta, A., Ohta, A., Madasu, M., Kini, R., Subramanian, M., Goel, N., & Sitkovsky, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901247 · Cited by 215
The cyclic AMP signaling pathway: Exploring targets for successful drug discovery (Review)
YAN, K., GAO, L.-N., CUI, Y.-L., ZHANG, Y., & ZHOU, X. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5005 · Cited by 214
Hatfield, S. M., Kjaergaard, J., Lukashev, D., Belikoff, B., Schreiber, T. H., Sethumadhavan, S., Abbott, R., Philbrook, P., Thayer, M., Shujia, D., et al. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1189-3 · Cited by 211
Radu, C. G., Nijagal, A., McLaughlin, J., Wang, L., & Witte, O. N. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409415102 · Cited by 211
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
Akl, M. R., Nagpal, P., Ayoub, N. M., Tai, B., Prabhu, S. A., Capac, C. M., Gliksman, M., Goy, A., & Suh, K. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8203 · Cited by 209
Csóka, B., Németh, Z. H., Virág, L., Gergely, P., Leibovich, S. J., Pacher, P., Sun, C.-X., Blackburn, M. R., Vizi, E. S., Deitch, E. A., et al. (2007) · Blood · doi:10.1182/blood-2007-01-065870 · Cited by 204
Adenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Cekic, C., Sag, D., Li, Y., Theodorescu, D., Strieter, R. M., & Linden, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101845 · Cited by 201
Katamura, K., Shintaku, N., Yamauchi, Y., Fukui, T., Ohshima, Y., Mayumi, M., & Furusho, K. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.10.4604 · Cited by 200
Bouma, M. G., van den Wildenberg, F. A., & Buurman, W. A. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.270.2.c522 · Cited by 200
Csóka, B., Himer, L., Selmeczy, Z., Vizi, E. S., Pacher, P., Ledent, C., Deitch, E. A., Spolarics, Z., Németh, Z. H., & Haskü, G. (2008) · The FASEB Journal · doi:10.1096/fj.08-107458 · Cited by 197
Adenosine and cAMP are potent inhibitors of the NF‐κB pathway downstream of immunoreceptors
Minguet, S., Huber, M., Rosenkranz, L., Schamel, W. W. A., Reth, M., & Brummer, T. (2005) · European Journal of Immunology · doi:10.1002/eji.200425524 · Cited by 197
Newick, K., O'Brien, S., Sun, J., Kapoor, V., Maceyko, S., Lo, A., Puré, E., Moon, E., & Albelda, S. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0263 · Cited by 197
Penix, L. A., Sweetser, M. T., Weaver, W. M., Hoeffler, J. P., Kerppola, T. K., & Wilson, C. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31964 · Cited by 195
Häusler, S. F. M., Montalbán del Barrio, I., Strohschein, J., Anoop Chandran, P., Engel, J. B., Hönig, A., Ossadnik, M., Horn, E., Fischer, B., Krockenberger, M., et al. (2011) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1040-4 · Cited by 193
Leone, R. D., Sun, I.-M., Oh, M.-H., Sun, I.-H., Wen, J., Englert, J., & Powell, J. D. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2186-0 · Cited by 190
Memory of Extracellular Adenosine A2A Purinergic Receptor-mediated Signaling in Murine T Cells
Koshiba, M., Kojima, H., Huang, S., Apasov, S., & Sitkovsky, M. V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25881 · Cited by 189
Szabó, C., Scott, G. S., Virág, L., Egnaczyk, G., Salzman, A. L., Shanley, T. P., & Haskó, G. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702040 · Cited by 187
Pharmacology of adenosine receptors in the vasculature
Tabrizchi, R., & Bedi, S. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00152-8 · Cited by 187
Morote–Garcia, J. C., Rosenberger, P., Nivillac, N. M. I., Coe, I. R., & Eltzschig, H. K. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.10.037 · Cited by 187
Differential Expression of Human Nucleoside Transporters in Normal and Tumor Tissue
Pennycooke, M., Chaudary, N., Shuralyova, I., Zhang, Y., & Coe, I. R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4205 · Cited by 186
Pidoux, G., & Taskén, K. (2010) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0010 · Cited by 184
CD73 and CD39 ectonucleotidases in T cell differentiation: Beyond immunosuppression
Bono, M. R., Fernández, D., Flores-Santibáñez, F., Rosemblatt, M., & Sauma, D. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.027 · Cited by 183
Wehbi, V. L., & Taskén, K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00222 · Cited by 181
Comerford, K. M., Lawrence, D. W., Synnestvedt, K., Levi, B. P., & Colgan, S. P. (2002) · The FASEB Journal · doi:10.1096/fj.01-0739fje · Cited by 180
Rao, S. R., Snaith, A. E., Marino, D., Cheng, X., Lwin, S. T., Orriss, I. R., Hamdy, F. C., & Edwards, C. M. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.402 · Cited by 179
Ma, S.-R., Deng, W.-W., Liu, J.-F., Mao, L., Yu, G.-T., Bu, L.-L., Kulkarni, A. B., Zhang, W.-F., & Sun, Z.-J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0665-0 · Cited by 179
CD39/Adenosine Pathway Is Involved in AIDS Progression
Nikolova, M., Carriere, M., Jenabian, M.-A., Limou, S., Younas, M., Kök, A., Huë, S., Seddiki, N., Hulin, A., Delaneau, O., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002110 · Cited by 177
Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Gattinoni, L., Ji, Y., & Restifo, N. P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0356 · Cited by 175
Gs Protein-Coupled Adenosine Receptor Signaling and Lytic Function of Activated NK Cells
Raskovalova, T., Huang, X., Sitkovsky, M., Zacharia, L. C., Jackson, E. K., & Gorelik, E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4383 · Cited by 175
del Barrio, I. M., Penski, C., Schlahsa, L., Stein, R. G., Diessner, J., Wöckel, A., Dietl, J., Lutz, M. B., Mittelbronn, M. G. A., Wischhusen, J., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0154-9 · Cited by 175
Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment
Cekic, C., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3581 · Cited by 174
ATP release via anion channels
Sabirov, R. Z., & Okada, Y. (2005) · Purinergic Signalling · doi:10.1007/s11302-005-1557-0 · Cited by 172
Selective Display of Histamine Receptors on Lymphocytes
Roszkowski, W., Plaut, M., & Lichtenstein, L. M. (1977) · Science · doi:10.1126/science.190677 · Cited by 172
Pain-relieving prospects for adenosine receptors and ectonucleotidases
Zylka, M. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.12.006 · Cited by 172
Desmet, C. J., Gallenne, T., Prieur, A., Reyal, F., Visser, N. L., Wittner, B. S., Smit, M. A., Geiger, T. R., Laoukili, J., Iskit, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222085110 · Cited by 172
Anti‐CD73 therapy impairs tumor angiogenesis
Allard, B., Turcotte, M., Spring, K., Pommey, S., Royal, I., & Stagg, J. (2014) · International Journal of Cancer · doi:10.1002/ijc.28456 · Cited by 171
Bouma, M. G., Jeunhomme, T. M., Boyle, D. L., Dentener, M. A., Voitenok, N. N., van den Wildenberg, F. A., & Buurman, W. A. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5400 · Cited by 171
Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion
Bivona, T. G., Wiener, H. H., Ahearn, I. M., Silletti, J., Chiu, V. K., & Philips, M. R. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200311093 · Cited by 171
Inhibition of the NF‐κB transcriptional activity by protein kinase A
Takahashi, N., Tetsuka, T., Uranishi, H., & Okamoto, T. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03157.x · Cited by 170
Koshiba, M., Rosin, D. L., Hayashi, N., Linden, J., & Sitkovsky, M. V. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12188-8 · Cited by 169
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
Inoue, Y., Yoshimura, K., Kurabe, N., Kahyo, T., Kawase, A., Tanahashi, M., Ogawa, H., Inui, N., Funai, K., Shinmura, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14434 · Cited by 169
Reinhardt, J., Landsberg, J., Schmid-Burgk, J. L., Ramis, B. B., Bald, T., Glodde, N., Lopez-Ramos, D., Young, A., Ngiow, S. F., Nettersheim, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0395 · Cited by 169
Extracellular NAD and ATP: Partners in immune cell modulation
Haag, F., Adriouch, S., Braß, A., Jung, C., Möller, S., Scheuplein, F., Bannas, P., Seman, M., & Koch-Nolte, F. (2007) · Purinergic Signalling · doi:10.1007/s11302-006-9038-7 · Cited by 168
Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐β
Regateiro, F. S., Howie, D., Nolan, K. F., Agorogiannis, E. I., Greaves, D. R., Cobbold, S. P., & Waldmann, H. (2011) · European Journal of Immunology · doi:10.1002/eji.201141512 · Cited by 166
Grant, M. B., Tarnuzzer, R. W., Caballero, S., Ozeck, M. J., Davis, M. I., Spoerri, P. E., Feoktistov, I., Biaggioni, I., Shryock, J. C., & Belardinelli, L. (1999) · Circulation Research · doi:10.1161/01.res.85.8.699 · Cited by 165
Dominant immunosuppression of dendritic cell function by prostate‐cancer‐derived exosomes
Salimu, J., Webber, J., Gurney, M., Al‐Taei, S., Clayton, A., & Tabi, Z. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1368823 · Cited by 165
TLR8 signaling enhances tumor immunity by preventing tumor‐induced T‐cell senescence
Ye, J., Ma, C., Hsueh, E. C., Dou, J., Mo, W., Liu, S., Han, B., Huang, Y., Zhang, Y., Varvares, M. A., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201403918 · Cited by 161
Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
Mittal, D., Sinha, D., Barkauskas, D., Young, A., Kalimutho, M., Stannard, K., Caramia, F., Haibe-Kains, B., Stagg, J., Khanna, K. K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0544 · Cited by 161
Saitoh, M., Nagai, K., Nakagawa, K., Yamamura, T., Yamamoto, S., & Nishizaki, T. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.01.020 · Cited by 160
The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?
Hu, Z. I., McArthur, H. L., & Ho, A. Y. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0234-y · Cited by 160
The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
Wilson, J. M., Ross, W. G., Agbai, O. N., Frazier, R., Figler, R. A., Rieger, J. M., Linden, J. M., & Ernst, P. B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801279 · Cited by 158
Merighi, S., Mirandola, P., Milani, D., Varani, K., Gessi, S., Klotz, K., Leung, E., Baraldi, P. G., & Borea, P. A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00111.x · Cited by 158
Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Simioni, C., Leung, E., Maclennan, S., Baraldi, P. G., & Borea, P. A. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032920 · Cited by 156
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2013) · Neoplasia · doi:10.1593/neo.131748 · Cited by 156
Altered purinergic signaling in CD73‐deficient mice inhibits tumor progression
Yegutkin, G. G., Marttila‐Ichihara, F., Karikoski, M., Niemelä, J., Laurila, J. P., Elima, K., Jalkanen, S., & Salmi, M. (2011) · European Journal of Immunology · doi:10.1002/eji.201041292 · Cited by 156
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
Waickman, A. T., Alme, A., Senaldi, L., Zarek, P. E., Horton, M. R., & Powell, J. D. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1155-7 · Cited by 155
Jiang, T., Xu, X., Qiao, M., Li, X., Zhao, C., Zhou, F., Gao, G., Wu, F., Chen, X., Su, C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4073-7 · Cited by 153
Host A2B Adenosine Receptors Promote Carcinoma Growth
Ryzhov, S. V., Novitskiy, S. V., Carbone, D. P., Biaggioni, I., Zaynagetdinov, R., Goldstein, A. E., Dikov, M. M., & Feoktistov, I. (2008) · Neoplasia · doi:10.1593/neo.08478 · Cited by 151
Zhi, X., Chen, S., Zhou, P., Shao, Z., Wang, L., Ou, Z., & Yin, L. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9081-y · Cited by 149
Dendritic cells tolerized with adenosine A2AR agonist attenuate acute kidney injury
Li, L., Huang, L., Ye, H., Song, S., Bajwa, A., Lee, S. J., Moser, E. K., Jaworska, K., Kinsey, G. R., Day, Y., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63170 · Cited by 149
Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer
Kazemi, M. H., Mohseni, S. R., Hojjat‐Farsangi, M., Anvari, E., Ghalamfarsa, G., Mohammadi, H., & Jadidi‐Niaragh, F. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25873 · Cited by 149
Bellingan, G. J., Maksimow, M., Howell, D. C. J., Stotz, M., Beale, R. J., Beatty, M., Walsh, T. S., Binning, A. R., Davidson, A., Kuper, M., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70259-5 · Cited by 148
Adenosine Extracellular Brain Concentrations and Role of A2AReceptors in Ischemia
Pedata, F., Corsi, C., Melani, A., Bordoni, F., & Latini, S. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03614.x · Cited by 145
Acquisition of new tumor cell properties by MSC-derived exosomes
Yang, Y., Bucan, V., Baehre, H., von der Ohe, J., Otte, A., & Hass, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3001 · Cited by 144
TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling
Abrahamsen, H., Baillie, G. S., Ngai, J., Vang, T., Nika, K., Ruppelt, A., Mustelin, T., Zaccolo, M., Houslay, M. D., & Taskén, K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4847 · Cited by 143
Raskovalova, T., Lokshin, A. E., Huang, X., Su, Y., Mandić, M., Zarour, H. M., Jackson, E. K., & Gorelik, E. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4249 · Cited by 142
Park, D. J., Min, H. K., & Rhee, S. G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45973-x · Cited by 141
Terp, M. G., Olesen, K. A., Arnspang, E. C., Lund, R. R., Lagerholm, B. C., Ditzel, H. J., & Leth‐Larsen, R. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301274 · Cited by 141
Who Is Who in Adenosine Transport
Pastor‐Anglada, M., & Pérez‐Torras, S. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00627 · Cited by 140
Rauen, T., Hedrich, C. M., Juang, Y., Tenbrock, K., & Tsokos, G. C. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.299313 · Cited by 139
Expression of CD39 on activated T cells impairs their survival in older individuals
Fang, F., Yu, M., Cavanagh, M. M., Hutter Saunders, J., Qi, Q., Ye, Z., Le Saux, S., Sultan, W., Turgano, E., Dekker, C. L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.002 · Cited by 138
Lokshin, A. E., Raskovalova, T., Huang, X., Zacharia, L. C., Jackson, E. K., & Gorelik, E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0478 · Cited by 138
Chen, Y., Harry, A., Li, J., Smit, M. J., Bai, X., Magnusson, R. P., Pieroni, J. P., Weng, G., & Iyengar, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.14100 · Cited by 137
Addi, A. B., Lefort, A., Hua, X., Libert, F., Communi, D., Ledent, C. A., Macours, P., Tilley, S. L., Boeynaems, J., & Robaye, B. (2008) · European Journal of Immunology · doi:10.1002/eji.200737781 · Cited by 136
Cited by
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
Metadata
- Authors
- Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-06
- Volume
- 10
- Pages
- 925-925
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2947747173
- Cited by
- 420
- References
- 411
- FWCI
- 33.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.